BG63276B1 - Метод за производство на модифициран инхибитор палидипин на колагениндуцирано тромбоцитно натрупване - Google Patents

Метод за производство на модифициран инхибитор палидипин на колагениндуцирано тромбоцитно натрупване Download PDF

Info

Publication number: BG63276B1
Authority: BG; Bulgaria
Prior art keywords: palidipine; asp; protein; seq; amino acid
Prior art date: 1994-09-12

Application number

BG101226A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG101226A (bg

Inventor

Christiane Noeske-Jungblut

Andreas Becker

Bernard Haendler

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-12

Filing date

1997-02-12

Publication date

2001-08-31

1997-02-12 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

1998-10-30 Publication of BG101226A publication Critical patent/BG101226A/xx

2001-08-31 Publication of BG63276B1 publication Critical patent/BG63276B1/bg

Links

238000000034 method Methods 0.000 title claims abstract description 33
238000004519 manufacturing process Methods 0.000 title claims abstract description 16
239000003112 inhibitor Substances 0.000 title description 15
108090000623 proteins and genes Proteins 0.000 claims abstract description 130
102000004169 proteins and genes Human genes 0.000 claims abstract description 126
235000018102 proteins Nutrition 0.000 claims abstract description 125
150000001413 amino acids Chemical class 0.000 claims abstract description 50
108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 36
102000008186 Collagen Human genes 0.000 claims abstract description 35
108010035532 Collagen Proteins 0.000 claims abstract description 35
229920001436 collagen Polymers 0.000 claims abstract description 35
235000001014 amino acid Nutrition 0.000 claims abstract description 32
238000000746 purification Methods 0.000 claims abstract description 26
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 25
210000001322 periplasm Anatomy 0.000 claims abstract description 25
239000013598 vector Substances 0.000 claims abstract description 25
235000003704 aspartic acid Nutrition 0.000 claims abstract description 21
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 21
230000009805 platelet accumulation Effects 0.000 claims abstract description 20
241000894006 Bacteria Species 0.000 claims abstract description 19
238000000605 extraction Methods 0.000 claims abstract description 18
210000004881 tumor cell Anatomy 0.000 claims abstract description 18
238000012546 transfer Methods 0.000 claims abstract description 17
206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 13
108091005804 Peptidases Proteins 0.000 claims abstract description 11
239000002299 complementary DNA Substances 0.000 claims abstract description 11
210000000805 cytoplasm Anatomy 0.000 claims abstract description 11
206010028980 Neoplasm Diseases 0.000 claims abstract description 9
239000004365 Protease Substances 0.000 claims abstract description 9
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 9
238000002955 isolation Methods 0.000 claims abstract description 8
201000011510 cancer Diseases 0.000 claims abstract description 7
241000124008 Mammalia Species 0.000 claims abstract description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 5
108020004414 DNA Proteins 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 22
102000002260 Alkaline Phosphatase Human genes 0.000 claims description 15
108020004774 Alkaline Phosphatase Proteins 0.000 claims description 15
241000588724 Escherichia coli Species 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 11
208000010125 myocardial infarction Diseases 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
201000001320 Atherosclerosis Diseases 0.000 claims description 7
102000053602 DNA Human genes 0.000 claims description 7
208000007536 Thrombosis Diseases 0.000 claims description 7
206010038563 Reocclusion Diseases 0.000 claims description 6
230000001580 bacterial effect Effects 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
238000005349 anion exchange Methods 0.000 claims description 3
238000005277 cation exchange chromatography Methods 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
230000011664 signaling Effects 0.000 claims description 2
230000004481 post-translational protein modification Effects 0.000 claims 2
238000000751 protein extraction Methods 0.000 claims 2
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 1
229910052711 selenium Inorganic materials 0.000 claims 1
239000011669 selenium Substances 0.000 claims 1
238000003776 cleavage reaction Methods 0.000 abstract description 5
230000007017 scission Effects 0.000 abstract description 5
210000004027 cell Anatomy 0.000 description 12
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
210000001772 blood platelet Anatomy 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000012360 testing method Methods 0.000 description 7
230000008569 process Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
241000282412 Homo Species 0.000 description 4
230000035508 accumulation Effects 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000006870 function Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
239000000047 product Substances 0.000 description 4
235000019419 proteases Nutrition 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000012134 supernatant fraction Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 3
DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 3
BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
JIVJQYNNAYFXDG-LKXGYXEUSA-N Cys-Thr-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JIVJQYNNAYFXDG-LKXGYXEUSA-N 0.000 description 3
IRKLTAKLAFUTLA-KATARQTJSA-N Cys-Thr-Lys Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCCCN)C(O)=O IRKLTAKLAFUTLA-KATARQTJSA-N 0.000 description 3
IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 3
MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 3
RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 3
TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 3
SYPULFZAGBBIOM-GVXVVHGQSA-N His-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N SYPULFZAGBBIOM-GVXVVHGQSA-N 0.000 description 3
DLFAACQHIRSQGG-CIUDSAMLSA-N Leu-Asp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DLFAACQHIRSQGG-CIUDSAMLSA-N 0.000 description 3
LMMBAXJRYSXCOQ-ACRUOGEOSA-N Lys-Tyr-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O LMMBAXJRYSXCOQ-ACRUOGEOSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
LPGSNRSLPHRNBW-AVGNSLFASA-N Pro-His-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 LPGSNRSLPHRNBW-AVGNSLFASA-N 0.000 description 3
XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 3
ABSXSJZNRAQDDI-KJEVXHAQSA-N Tyr-Val-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ABSXSJZNRAQDDI-KJEVXHAQSA-N 0.000 description 3
NMPXRFYMZDIBRF-ZOBUZTSGSA-N Val-Asn-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N NMPXRFYMZDIBRF-ZOBUZTSGSA-N 0.000 description 3
FRUYSSRPJXNRRB-GUBZILKMSA-N Val-Cys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FRUYSSRPJXNRRB-GUBZILKMSA-N 0.000 description 3
AHHJARQXFFGOKF-NRPADANISA-N Val-Glu-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N AHHJARQXFFGOKF-NRPADANISA-N 0.000 description 3
AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
108010013835 arginine glutamate Proteins 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000020764 fibrinolysis Effects 0.000 description 3
239000012634 fragment Substances 0.000 description 3
108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
108010087846 prolyl-prolyl-glycine Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
108010009962 valyltyrosine Proteins 0.000 description 3
ZABMJSAHPWHMNM-QCOJBMJGSA-N (2s)-6-amino-2-[[(2s)-1-[2-[[(2s)-1-[(2s)-4-carboxy-2-[[2-[[(2s)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]butanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@H](C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCCN)C(O)=O)CCC1 ZABMJSAHPWHMNM-QCOJBMJGSA-N 0.000 description 2
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 description 2
YNOCMHZSWJMGBB-GCJQMDKQSA-N Ala-Thr-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O YNOCMHZSWJMGBB-GCJQMDKQSA-N 0.000 description 2
GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 2
UWXFFVQPAMBETM-ZLUOBGJFSA-N Cys-Asp-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UWXFFVQPAMBETM-ZLUOBGJFSA-N 0.000 description 2
KABHAOSDMIYXTR-GUBZILKMSA-N Cys-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N KABHAOSDMIYXTR-GUBZILKMSA-N 0.000 description 2
HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 2
XQHSBNVACKQWAV-WHFBIAKZSA-N Gly-Asp-Asn Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O XQHSBNVACKQWAV-WHFBIAKZSA-N 0.000 description 2
VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 2
AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 2
241000545744 Hirudinea Species 0.000 description 2
241000237902 Hirudo medicinalis Species 0.000 description 2
QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 2
JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 description 2
PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 2
HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 2
MIROMRNASYKZNL-ULQDDVLXSA-N Lys-Pro-Tyr Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MIROMRNASYKZNL-ULQDDVLXSA-N 0.000 description 2
MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 2
XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 2
GFRIEEKFXOVPIR-RHYQMDGZSA-N Thr-Pro-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O GFRIEEKFXOVPIR-RHYQMDGZSA-N 0.000 description 2
COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
108010093581 aspartyl-proline Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
108010037850 glycylvaline Proteins 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
108010055353 lysyl-prolyl-glycyl-glutamyl-prolyl-glycyl-prolyl-lysine Proteins 0.000 description 2
108010064235 lysylglycine Proteins 0.000 description 2
108010054155 lysyllysine Proteins 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000008024 pharmaceutical diluent Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
238000011160 research Methods 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000003998 snake venom Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 1
TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 description 1
HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
JPPLRQVZMZFOSX-UWJYBYFXSA-N Asn-Tyr-Ala Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 JPPLRQVZMZFOSX-UWJYBYFXSA-N 0.000 description 1
HOQGTAIGQSDCHR-SRVKXCTJSA-N Asp-Asn-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HOQGTAIGQSDCHR-SRVKXCTJSA-N 0.000 description 1
PXLNPFOJZQMXAT-BYULHYEWSA-N Asp-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O PXLNPFOJZQMXAT-BYULHYEWSA-N 0.000 description 1
DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
HICVMZCGVFKTPM-BQBZGAKWSA-N Asp-Pro-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HICVMZCGVFKTPM-BQBZGAKWSA-N 0.000 description 1
NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
102100021277 Beta-secretase 2 Human genes 0.000 description 1
101710150190 Beta-secretase 2 Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 1
CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
101100181398 Haementeria officinalis LAPP gene Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
FDINZVJXLPILKV-DCAQKATOSA-N Pro-His-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O FDINZVJXLPILKV-DCAQKATOSA-N 0.000 description 1
LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
SHTKRJHDMNSKRM-ULQDDVLXSA-N Pro-Tyr-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O SHTKRJHDMNSKRM-ULQDDVLXSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 1
101710099833 Venom protein Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002001 anti-metastasis Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
108010068265 aspartyltyrosine Proteins 0.000 description 1
238000010352 biotechnological method Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
108010051489 calin Proteins 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
108010015792 glycyllysine Proteins 0.000 description 1
STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
108010017391 lysylvaline Proteins 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
108010000867 moubatin Proteins 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
108010081580 platelet adhesion inhibitor Proteins 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
101150075675 tatC gene Proteins 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BG101226A 1994-09-12 1997-02-12 Метод за производство на модифициран инхибитор палидипин на колагениндуцирано тромбоцитно натрупване BG63276B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94250224		1994-09-12
PCT/EP1995/003573 WO1996008563A1 (fr)	1994-09-12	1995-09-11	Procede de preparation d'un inhibiteur modifie de l'agregation plaquettaire induite par le collagene: la pallidipine

Publications (2)

Publication Number	Publication Date
BG101226A BG101226A (bg)	1998-10-30
BG63276B1 true BG63276B1 (bg)	2001-08-31

Family

ID=8217517

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101226A BG63276B1 (bg)	1994-09-12	1997-02-12	Метод за производство на модифициран инхибитор палидипин на колагениндуцирано тромбоцитно натрупване

Country Status (22)

Country	Link
US (1)	US5882887A (fr)
EP (1)	EP0781334A1 (fr)
JP (1)	JPH10505502A (fr)
CN (1)	CN1075836C (fr)
AU (1)	AU701643B2 (fr)
BG (1)	BG63276B1 (fr)
BR (1)	BR9508910A (fr)
CA (1)	CA2199719A1 (fr)
CZ (1)	CZ76297A3 (fr)
FI (1)	FI971013A7 (fr)
HU (1)	HU222398B1 (fr)
IL (1)	IL115272A0 (fr)
MX (1)	MX9701720A (fr)
NO (1)	NO971110L (fr)
NZ (1)	NZ293261A (fr)
PL (1)	PL184617B1 (fr)
RO (1)	RO117971B1 (fr)
RU (1)	RU2186110C2 (fr)
SI (1)	SI9520093A (fr)
SK (1)	SK29297A3 (fr)
WO (1)	WO1996008563A1 (fr)
ZA (1)	ZA957649B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL200384B1 (pl) *	1999-03-18	2008-12-31	Merck Patent Gmbh	Polipeptyd blokujący adhezję płytek krwi, sposób jego otrzymywania, zastosowanie i zawierający go preparat farmaceutyczny
EP1831395A1 (fr) *	2004-12-28	2007-09-12	Ares Trading S.A.	Compositions et procedes de traitement de la schizophrenie et de troubles associes
US7691839B2 (en)	2005-09-28	2010-04-06	Biovascular, Inc.	Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20110034396A1 (en) *	2005-09-28	2011-02-10	Biovascular, Inc.	Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
TWI391143B (zh) *	2005-11-04	2013-04-01	Otsuka Pharma Co Ltd	血小板凝集抑制劑組成物
US9617302B2 (en) *	2011-06-14	2017-04-11	National Taiwan University	Peptide compounds for inhibition of platelet aggregation
FR2979346B1 (fr)	2011-08-23	2013-09-27	Univ Joseph Fourier	Nanocorps anti-vcam-1
EP2812012A1 (fr)	2012-02-07	2014-12-17	Global Bio Therapeutics USA, Inc.	Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations
NZ705899A (en)	2012-09-07	2018-08-31	Inst Nat Sante Rech Med	Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
MX378673B (es)	2013-08-08	2025-03-10	Global Bio Therapeutics Inc	Dispositivo de sujecion para procedimientos minimamente invasivos y usos del mismo.
FR3058143B1 (fr)	2016-10-27	2021-03-12	Univ Grenoble Alpes	Nanocorps anti-tau
EP4340855A1 (fr)	2021-08-13	2024-03-27	Triovance Holding LLC	Composition de substitut de peau et ses procédés de production et d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03503596A (ja) *	1987-06-24	1991-08-15	ノボ・ノルディスク　エー／エス	蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用
RU2128705C1 (ru) *	1991-09-05	1999-04-10	Шеринг Аг	Протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов млекопитающих, рекомбинантный протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов, фрагмент днк, кодирующий рекомбинантный протеин, вектор экспрессии (варианты), штамм культивируемых животных клеток внк - продуцент рекомбинантного протеина (варианты), способ получения рекомбинантного протеина, фармацевтическая композиция
US5756454A (en) *	1991-09-05	1998-05-26	Schering Aktiengesellschaft	Collagen-induced platelet aggregation inhibitor
US5705362A (en) *	1992-05-25	1998-01-06	Gist-Brocades, N.V.	Modified signal sequences

1995
- 1995-09-11 CZ CZ97762A patent/CZ76297A3/cs unknown
- 1995-09-11 HU HU9701823A patent/HU222398B1/hu not_active IP Right Cessation
- 1995-09-11 WO PCT/EP1995/003573 patent/WO1996008563A1/fr not_active Ceased
- 1995-09-11 SK SK292-97A patent/SK29297A3/sk unknown
- 1995-09-11 CN CN95195002A patent/CN1075836C/zh not_active Expired - Fee Related
- 1995-09-11 MX MX9701720A patent/MX9701720A/es unknown
- 1995-09-11 EP EP95932714A patent/EP0781334A1/fr not_active Withdrawn
- 1995-09-11 JP JP8509898A patent/JPH10505502A/ja not_active Ceased
- 1995-09-11 CA CA002199719A patent/CA2199719A1/fr not_active Abandoned
- 1995-09-11 RO RO97-00444A patent/RO117971B1/ro unknown
- 1995-09-11 US US08/793,294 patent/US5882887A/en not_active Expired - Fee Related
- 1995-09-11 RU RU97105821/13A patent/RU2186110C2/ru not_active IP Right Cessation
- 1995-09-11 BR BR9508910A patent/BR9508910A/pt not_active Application Discontinuation
- 1995-09-11 SI SI9520093A patent/SI9520093A/sl unknown
- 1995-09-11 PL PL95319078A patent/PL184617B1/pl unknown
- 1995-09-11 AU AU35657/95A patent/AU701643B2/en not_active Ceased
- 1995-09-11 NZ NZ293261A patent/NZ293261A/en unknown
- 1995-09-12 ZA ZA957649A patent/ZA957649B/xx unknown
- 1995-09-12 IL IL11527295A patent/IL115272A0/xx unknown
1997
- 1997-02-12 BG BG101226A patent/BG63276B1/bg unknown
- 1997-03-11 NO NO971110A patent/NO971110L/no unknown
- 1997-03-11 FI FI971013A patent/FI971013A7/fi unknown

Also Published As

Publication number	Publication date
NO971110L (no)	1997-05-07
PL184617B1 (pl)	2002-11-29
NO971110D0 (no)	1997-03-11
FI971013A0 (fi)	1997-03-11
WO1996008563A1 (fr)	1996-03-21
AU701643B2 (en)	1999-02-04
HUT76972A (hu)	1998-01-28
JPH10505502A (ja)	1998-06-02
HU222398B1 (hu)	2003-06-28
SK29297A3 (en)	1997-10-08
CA2199719A1 (fr)	1996-03-21
CZ76297A3 (cs)	1998-01-14
BR9508910A (pt)	1997-10-28
FI971013A7 (fi)	1997-03-11
EP0781334A1 (fr)	1997-07-02
PL319078A1 (en)	1997-07-21
IL115272A0 (en)	1995-12-31
RU2186110C2 (ru)	2002-07-27
MX9701720A (es)	1997-06-28
SI9520093A (en)	1997-08-31
CN1159828A (zh)	1997-09-17
CN1075836C (zh)	2001-12-05
NZ293261A (en)	1998-11-25
BG101226A (bg)	1998-10-30
US5882887A (en)	1999-03-16
ZA957649B (en)	1996-04-15
RO117971B1 (ro)	2002-11-29
AU3565795A (en)	1996-03-29

Publication	Publication Date	Title
JP4344136B2 (ja)	2009-10-14	アポリポタンパク質類似体
JP2000515370A (ja)	2000-11-21	膜結合剤と可溶性ペプヂド性化合物の結合体
BG63276B1 (bg)	2001-08-31	Метод за производство на модифициран инхибитор палидипин на колагениндуцирано тромбоцитно натрупване
CA2130900C (fr)	2009-04-14	Domaines therapeutiques du facteur von willebrand
EP0687731B1 (fr)	1999-02-03	Vecteur sécrétoire, microorganismes transformés contenant ledit vecteur et production d'un produit à partir dudit microorganisme
US6274365B1 (en)	2001-08-14	Pharmaceutical composition having an endoproteolytic activity
KR100232683B1 (ko)	1999-12-01	콜라겐에 의해 유도되는 혈소판 응집 억제제
MXPA97001720A (en)	1997-06-01	Process for the manufacture of a modified palidipine, inhibitor of platelet aggregation induced by colag
JPH04503761A (ja)	1992-07-09	Ｐａｉ―２の変異体
EP0885956A1 (fr)	1998-12-23	Préparation pharmaceutique à activité endoprotéolytique; procédé de traitement endoprotéolytique des protéines (précurseurs) et de production (micro)biologique des protéines
US8975370B2 (en)	2015-03-10	Inhibitor proteins of a protease and use thereof
RU2183214C2 (ru)	2002-06-10	Природный и рекомбинантный ингибиторы тромбина, их получение и применение
EP0693925B1 (fr)	2002-02-13	Production d'un inhibiteur du facteur xa de la sangsue hirudo medicinalis sous forme recombinee
JP2798573B2 (ja)	1998-09-17	ヒト好中球エラスターゼ阻害活性を有する天然型ポリペプチドおよびそれを含有する医薬製剤
CN115572329B (zh)	2024-02-06	一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法
KR101034901B1 (ko)	2011-05-17	아포리포단백질 유사체
JPH0353893A (ja)	1991-03-07	リンホトキシン誘導体の製造方法